The Efficacy and Six-Week Tolerability of Simvastatin 80 and 160 mg/Day
- 1 January 1997
- journal article
- clinical trial
- Published by Elsevier in The American Journal of Cardiology
- Vol. 79 (1), 38-42
- https://doi.org/10.1016/s0002-9149(96)00742-4
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Benefits and Risks of HMG-CoA Reductase Inhibitors in the Prevention of Coronary Heart Disease A ReappraisalDrug Safety, 1996
- Reduction of LDL Cholesterol by 25% to 60% in Patients With Primary Hypercholesterolemia by Atorvastatin, a New HMG-CoA Reductase InhibitorArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Cholesterol Reduction Yields Clinical BenefitCirculation, 1995
- Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS)The Lancet, 1994
- By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?BMJ, 1994
- Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: Evidence for reduced assembly and secretion of triglyceride-rich lipoproteinsMetabolism, 1992
- Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations.BMJ, 1991
- Comparison of Plasma Profiles of Lovastatin (Mevinolin), Simvastatin (Epistatin) and Pravastatin (Eptastatin) in the DogClinical Drug Investigation, 1990
- Serum cholesterol, other risk factors, and cardiovascular disease in a Japanese cohortJournal of Chronic Diseases, 1984
- Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent.Proceedings of the National Academy of Sciences, 1980